ALLMedicine™ Systemic Mastocytosis Center
Research & Reviews 515 results
https://doi.org/10.1097/RLU.0000000000004564
Clinical Nuclear Medicine; García Vicente AM, Noriega Álvarez E et. al.
Feb 3rd, 2023 - Nocardia infection (nocardiosis) is usually acquired by inhalation; so pulmonary nocardiosis is the most common clinical presentation. Extrapulmonary localization occurs through hematogenous dissemination or contiguous spread. Nocardia can involve...
https://clinicaltrials.gov/ct2/show/NCT03770273
Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875486
BMC Cancer; Tiryaki TO, Özkan SG et. al.
Jan 25th, 2023 - Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wi...
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD
Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.
https://clinicaltrials.gov/ct2/show/NCT04910685
Jan 19th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
Guidelines 1 results
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Drugs 252 results see all →
Clinicaltrials.gov 46 results
https://clinicaltrials.gov/ct2/show/NCT03770273
Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://clinicaltrials.gov/ct2/show/NCT04910685
Jan 19th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://clinicaltrials.gov/ct2/show/NCT02561988
Jan 13th, 2023 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...
https://clinicaltrials.gov/ct2/show/NCT05186753
Jan 11th, 2023 - This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of CGT9486 plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdv...
https://clinicaltrials.gov/ct2/show/NCT03794076
Jan 6th, 2023 - Schizophrenia (SZ) extracts a heavy personal and public health cost, primarily because there is no effective treatment. Though many drugs are currently available, the majority provide only partial relief for psychotic phenomena and none guarantee ...
News 97 results
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD
Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.
https://www.mdedge.com/dermatology/article/260439/contact-dermatitis/cutaneous-manifestations-hereditary-alpha-tryptasemia
Allison Kranyak, MD, Marshall Shuler, MD et. al.
Jan 3rd, 2023 - Hereditary alpha tryptasemia (HaT), an autosomal-dominant disorder of tryptase overproduction, was first described in 2014 by Lyons et al. 1 It has been associated with multiple dermatologic, allergic, gastrointestinal (GI) tract, neuropsychiatric,.
https://www.mdedge.com/familymedicine/article/260254/dermatology/incidental-skin-finding
MDedge Family Medicine;
Dec 19th, 2022 - This patient was given a diagnosis of cutaneous mastocytosis. The condition was previously known as urticaria pigmentosa, but in 2016 the World Health Organization reclassified the disease to better suit its pathophysiology as a myeloid cell disor.
https://www.onclive.com/view/avapritinib-meets-primary-and-secondary-end-points-in-pioneer-trial-in-non-advanced-systemic-mastocytosis
Aug 17th, 2022 - Treatment with avapritinib (Ayvakit) led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis, meeting the p...
https://www.onclive.com/view/bezuclastinib-demonstrates-early-promise-in-advanced-systemic-mastocytosis
Jun 13th, 2022 - Bezuclastinib (formerly PLX 9486) showcased early signs of clinical activity in that it resulted in a meaningful reduction in serum tryptase levels, as well as reductions in mast cell (MC) burden and KIT D816V variant allele frequency (VAF), in ad...
